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Abstract
Objective: The impact of breast cancer is immense for all women, but the literature reveals an even greater impact on women of color and
among socially and economically disadvantaged populations. Persistent differences in incidence and outcome are undoubtedly due to multiple
factors, but one element in poor outcome may be treatment choice. Those treatments shown to be related to best outcomes are less likely to be
chosen by certain groups of women. The effects of economic and cultural factors on breast cancer treatment choice have not been thoroughly
explored; these factors must be understood if health care professionals are to intervene effectively to address disparities and improve breast
cancer outcomes for all women.
Methods: A review of the breast cancer literature was conducted in order to: (1) describe breast cancer disparities in the United States; (2)
delineate factors that might contribute to those disparities; (3) assess possible mitigating factors for predominant causes; (4) begin to decide
how health care interventions might allay the factors that contribute to disparities in breast cancer incidence and mortality.
Results: Breast cancer incidence and outcome disparities in the United States are due to multiple interacting factors. These include
information about treatment, different types of treatment, the emotional context of decision-making, and patient preference for level of
involvement. Treatment decision-making is complex.
Conclusion: Health literacy and level of decision-making involvement, both embedded in social and economic reality, are key components in
breast cancer treatment decision-making and may contribute to breast cancer disparities in the United States. Current models of shared
decision-making may not be generalizable to all breast cancer patients.
Practice implications: Optimal breast cancer outcomes for all women depend on culturally and ethnically appropriate professional support.
# 2006 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
With widely available screening for early detection and
definitive therapy with tested agents, breast cancer need not
be a universally lethal diagnosis. Yet breast cancer levies a
high cost for women, particularly those in the ethnically and
economic diverse populations least likely to be health
literate. Not only can screening measures be underused and
ineffective in these communities, but socioeconomic, racial,
and ethnic disparities persist in the use of the best evidence-
based treatments (with the best outcomes) for diagnosed
breast cancer [1–5].
Treatment decisions are complex for those fortunate
women and families who have access to care, have health
care coverage, and who possess adequate knowledge and
skill in navigating the health care delivery system. For
women who struggle with any of these factors, the task is
even more troublesome. It is appreciated that treatment
decisions are complex and linked to patient outcomes, but
the interactive decision-making process between the patient,
family, and health care team has not been studied in depth
among those populations likely to have the poorest
outcomes. Moreover, the role of treatment decision-making
in contributing to breast cancer disparities is poorly
understood. This paper serves to explore disparities in
treatment and decision-making in U.S. women, specifically
women of color, women who are disadvantaged, and
minority women.
2. Methods
In the context of a larger project, searches were
conducted on major health care databases (including
MEDLINE, PubMed, OVID, and CINAHL), to identify
articles concerning breast cancer (including incidence,
treatment, and outcomes) in all populations of women.
English language articles concerning breast cancer pub-
lished in refereed medical, nursing, health education,
epidemiology, and public health journals were included in
the initial review. Reference lists were then used to pull past
articles upon which current literature was based. Most
articles were published within the last five years, but older
research was included if it was not replicated or replaced
with more current studies. Both qualitative and quantitative
studies were assessed for scientific integrity in the context of
appropriate disciplines. For example, incidence figures
concerning breast cancer in various cultural, ethnic, and
economic populations were taken from population health
and epidemiological sources. Treatment trials tended to
appear in the medical literature. Studies concerning
treatment decision-making were considered valid if the
study was considered methodologically sound in any
disciplinary literature. Searching continued until saturation
was reached.
Breast cancer disparities research was the second focus of
the search. Disparities in cancer are a major research focus
of the National Cancer Institute [6], so current literature was
plentiful. Those articles served as the basis for this inquiry,
supplemented by the latest studies in health care decision-
making and cancer decision-making found in previous
searches.
3. Findings
The findings from this search resulted in several themes.
These are described in detail below and include breast
cancer disparities in the United States across ethnic and
socioeconomic groups; treatment disparities; decision-
making about treatment, level of involvement in the
decision-making process; and the complexity of decision-
making.
3.1. Race and breast cancer incidence and mortality
disparities
Jemal et al. [7], citing the National Center for Health
Statistics, state that nearly 216,000 women were expected to
be diagnosed with breast cancer in the United States in 2004.
As seen in Table 1, differences in breast cancer incidence
and mortality exist in the United States. The national
incidence rate for breast cancer is about 135 per 100,000 but
relative risk and incidence rates vary by race and ethnicity.
Breast cancer incidence rates for women of color are
lower than for Caucasian women, but mortality rates are
disproportionately higher. Disparities in survival are
partially a function of diagnosis at a more advanced stage
[8–10], possibly related to limited information available
about breast cancer risk factors, limited opportunities for
screening, or cultural beliefs about risks and mortality
[11,12]. Other factors, including disparate effects of
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therapy, may also play a role in mortality rates as minority
women display worse stage-specific survival [7,9,13].
Disparities may also emerge from interactions between
genetic predisposition and various risk factors such as the
effect of culturally related behaviors such as dietary and
exercise patterns in certain individuals [14]. There are also
links between race/ethnicity and indicators of disadvantage,
such as low income, low educational level, and lack of
health insurance that are themselves independently asso-
ciated with advanced stage diagnosis and diminished
survival [15–18]. To magnify the deleterious effect of
social and economic risk factors, current treatments for
palpable breast masses and diagnosed stages I and II cancers
are reportedly used less frequently by disadvantaged and
minority patients [1].
3.2. Disparate breast cancer treatment patterns
Certain women are less likely to choose treatment
measures validated as most effective through clinical trials
[1]. Health care professionals search for the underlying
causes of this threat to public health, but as with most
intricate social phenomena, multiple forces have an impact
on treatment disparities, including treatment decision-
making.
The type of treatment a woman receives for early stage
breast cancer has complex determinants, including clinical
variables such as patient age and the tumor size, location,
and grade at diagnosis [19]. In addition, a patient’s health
insurance status may have an impact on her seeking or
receiving care [20]. Physician practice patterns are known to
vary by individual and by geographic area [21–25] as well as
by hospital teaching status [22]. Several studies have shown
that women choose various treatments related to geographic
proximity to radiation treatment and other health care
facilities [26–29].
Interpersonal variables may also have an impact on
treatment decisions, such as the quality of the doctor–patient
interaction [28–30], the availability of treatment-related
knowledge (culturally and education-style appropriate), and
the presence or absence of preconceived notions concerning
treatment options [31–35]. The literature suggests that
ethnically diverse and disadvantaged women are less likely
to receive culturally appropriate information from their
physicians [2], to be involved in the therapeutic decision
[3,4], and to receive definitive treatment for early stage
breast cancer [5].
It might be anticipated that treatment patterns will vary,
given the number of interacting contributing factors, but one
would not expect treatment patterns to vary so strongly along
cultural, racial, ethnic, and economic boundaries. In fact,
with the wide availability of sophisticated, trials-based
information concerning best practice in breast cancer, it is
surprising that more consistency is not seen in breast cancer
treatment.
3.2.1. Mastectomy versus breast-conserving therapy
(BCT)
Strong randomized trial evidence on equivalent survival
following mastectomy versus breast conserving therapy has
been available since the 1980s [36–38]. The 1990 NIH
consensus statement on treatment of early stage breast
carcinoma recommended BCT [39] and confirmed the
wisdom of the recommendation through emergent evidence
[40–42]. However, a high proportion of women categorized
as low income and/or less educated continue to receive
mastectomy rather than BCT [5,28,31,43–48].
The origins of this disparity in treatment could be related
to any of the factors mentioned above, or to other factors
associated with patient choice. Researchers and physicians
have assumed that ‘‘informed’’ women would choose a less
disfiguring procedure over mastectomy, but the under-
pinnings of the decision are apparently more complex than
simple body image concerns or the need for information.
Even well-informed women’s apprehension about the risk of
recurrent disease in the operated breast and the need to
receive radiation therapy or other relatively disruptive
ongoing treatments may outweigh other concerns
[43,45,49].
There is conjecture that as more economically and
ethnically diverse groups of patients are given greater input
into their health care decisions, they choose treatments that
may not yield the greatest health benefit or that may not
conform to the physician’s idea of the ideal treatment for that
woman [45,50]. There is the possibility that a woman’s
choice of mastectomy reflects an inadequate appreciation for
the evidence against that decision, but there is an alternative
explanation. The decision may reflect a concomitant
avoidance of inconvenient adjuvant therapies that reflects
her taking into consideration the total impact of her decision
on herself and her family. It is intriguing to posit that health
care barriers and the inconvenience of the system for many
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Table 1
Breast cancer incidence and mortality in women
Incidence per 100,000 Mortality
per 100,000
National 2004 projection (National Center Health Statistics)
Overall 135 27.7
Hispanic 90 17.9
African American 122 35.9
Non-Hispanic White 141 27.2
Texas 1997–2001 (Texas Cancer R0egistry)
Overall 119.3 25.9
Hispanic 81.8 19.6
African American 113.1 38.3
Non-Hispanic White 130.5 26
Bexar County 2000 (Texas Cancer Registry)
Overall 123.1 25.9
Hispanic 91.9 19.8
African American 115.3 38.2
Non-Hispanic White 150.5 26
women, including those without transportation or childcare,
might weigh more heavily into a woman’s decision than
physicians realized. As was previously mentioned, there is
evidence that some women choose treatment regimen based
on their geographic proximity to radiation treatment and other
health care facilities [26–29]. Many women must consider
emotional and experiential issues as well as practical issues in
making a decision for mastectomy, including pressures not to
miss work, or be absent from family responsibilities during
radiation therapy or how financial issues may spring from not
having health insurance coverage.
3.2.2. Adjuvant therapies: chemotherapy and radiation
African American, Mexican American, Puerto Rican,
uninsured, and low income women in the United States
receive what is widely considered to be substandard therapy
(such as lumpectomy without subsequent radiation) at high
rates [20,46–49]. The public health implications of such
statistics are alarming: women who fail to receive post-
lumpectomy radiation therapy have a 39% risk of cancer
recurrence in the operated breast versus 14% with radiation
[40]. Inadequate treatment has also been associated with
reduced survival in observational studies [51–53]. What is
not understood is how those treatment decisions are made:
are women not adequately informed, do they not understand
their options, or do they forgo treatments that entail multiple
visits and/or long convalescence?
While all women may encounter these issues, for those
who are disadvantaged, the issues may pose a highly
individualized role in personal decision-making. Thus,
supporting breast cancer treatment decision-making is more
complex than just providing treatment information. Clear,
comprehensive information regarding not only treatment
options, but also length of time required for treatment,
physiological impact, and unanticipated financial and life-
style costs must be included.
3.3. Breast cancer treatment decision-making
It is widely assumed that treatment decisions in the 21st
century will emerge from a collaborative process between
the patient and the provider, but there is no published
evidence concerning the actual contribution of shared
decision-making to the eventual decision outcome or to the
health status outcome in any group of patients. If disparities
in survival are to be addressed, the entire process and context
of breast cancer treatment decision-making must be
understood from the patient’s perspective.
3.3.1. The role of information in breast cancer decision-
making
Traditionally, health care knowledge has been considered
necessary and sufficient in supporting patient treatment
decision-making. Yet the utility of knowledge is influenced by
the decision-making context and a myriad of intrapersonal
dynamics. In health care settings, patients are faced with
foreign or technical terms, complex ideas, multiple options,
and the need to differentially weigh the relative value of
unfamiliar choices. In order to cope, patients may reduce their
decision burden using potentially maladaptive strategies such
as allowing the most readily understood factor to prevail or
denying the existence of certain bothersome factors.
The cognitive burden of decisions can be reduced through
materials that provide details on procedures, risks, and
benefits in a logically structured format. Such tools have been
applied in a variety of clinical settings and they have been
demonstrated to not only improve knowledge but to reduce
decisional conflict [54–61]. For example, a ‘‘decision board’’
is a poster-sized display upon which information regarding
treatment options, potential complications, and treatment
outcomes is printed. A sliding panel allows portions of the
display to be revealed sequentially as the patient and presenter
move through the content together. One advantage of the
decision board over other informational aids such as multi-
media interventions [55,56] is that it presents information in
distinct, rather isolated and sequential pieces, limiting the
amount of information to be processed at any one moment.
The activity also is highly interactive, consistent with
evidence that women facing breast cancer decisions desire
interpersonal communication in health care decisions [2,62].
Cognitive retention issues are addressed as patient retain
materials. Such tools are designed to support analytic learning
and in those patients that are comfortable with analysis,
improved satisfaction has been demonstrated [53,63].
The intent of decision support tools is to provide concrete
evidence for a treatment decision. But simply reducing
cognitive burden is not enough. Gurmankin et al. [64] and
decision support ethicist Ubel [65] warn that the use of
decision support tools may lead patients to decisions that are
inconsistent with their own stated preferences. Sanders and
Skevington explain that providing information differs from
providing ‘‘interpretation,’’ or ‘‘adequate knowledge’’ [66].
In their theory, they state that in unfamiliar situations, people
will construct preferences that vary according to social and
contextual variables. Patients’ perceptions, then, perhaps
result as much from providers’ manner of interaction as from
the actual information that is imparted. This can produce a
difference between what the health care team perceives as
having been presented and what the breast cancer patient and
family have perceived, demonstrating a deficit in what
Sanders would put forth as ‘‘adequate knowledge.’’
The literature supports this theoretical model. In Keating
et al.’s studies [67,68], 29% of women eligible for breast
conserving treatment did not recall their surgeon discussing
the procedure. Patients and surgeons actually disagreed in
one-third of cases as to whether BCT had even been
discussed; disagreement doubled in a less-educated patient
group. A similar proportion of women in another study
(33%) did not perceive that they had a choice of procedure at
all [50]. If information is not heard by patients, choices
cannot be properly structured and weighed. Whether the lack
of perception can be attributed to emotional context,
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cognitive inabilities, or faulty communication, the outcome
is the same: women and the health care team are not working
together to make the best breast cancer treatment decisions
for individual women. Information, then, while indeed
central to patient decision-making, is necessary but not
sufficient. Other facets of decision-making – attitudes,
culture, experience, and emotion – may affect the perception
of information or render facts inconsequential.
3.3.2. Emotional context
Health care decision-making is laden with emotional as
well as cognitive determinants. Lam et al. [69] caution that
providing information is not enough to ensure health literacy
and sound decision-making. Patients can be emotionally
overwhelmed by decision-making; the Chinese women Lam
interviewed stated that they had insufficient knowledge to
make a critical treatment decision. They described this
feeling as ‘‘gambling’’ with their health. Mcvea et al. [28]
described similar responses within their Nebraska cohort.
Women involved in the Nuestras Historias [70] project
(2004) in San Antonio echoed many such comments.
Patient, family, and physician variables are part of the
emotional context in decision-making. Culver et al. [71,72]
state that reactions to the diagnosis and coping skills vary
between ethnic groups. Spencer et al. [73] stated that
Hispanic women seem to be more affected in several life
domains and may make decisions differently because of it.
The emotional context of health care decision-making is
embedded in culture and role theory, so no breast cancer
treatment decision can be supported without an appreciation
of the social and familial emotional context. Additionally,
the emotional context may influence the patient’s interest
and ability to be involved in the treatment decision process.
3.3.3. Patient preference for level of involvement
It has been shown that individual patients differ in their
preference for level of decision-making involvement, from
taking complete authority for a decision, to shared decision-
making with their clinician, to deferring to the clinician’s
decision [22,62,74–76]. This added variable further com-
plicates how treatment decisions are made. Not only is the
emotional context at play but also appropriate information
should be presented in a culturally appropriate manner.
Thus, the health care team must be able to assess quickly and
accurately how much authority a woman wants to exercise in
decision-making. Then he or she must respond to that
assessment by structuring a dynamic situation to provide
appropriate levels of support and validation for that
individual. In today’s health care delivery system, those
tasks are likely to be difficult due to time constraints for
providers.
3.3.4. The overwhelming complexity of health care
decision-making
Deber et al. [77] suggest that treatment decision-making
may be even more convoluted than simply information,
context, and emotion: decisions are made in a dynamic
process of structuring choices (problem solving) and
weighing those choices through two (often simultaneously
operating) decision-making modes, analytic and experien-
tial. The analytic mode applies conscious reasoning,
weighing facts to gradually construct decisions. This mode
is most easily addressed in practice with tools to present
factual information. In contrast, the experiential mode
applies to emotional responses, associations, and intuition to
judging information, including cultural, ethnic, and eco-
nomic elements. Although many health care interventions
have addressed the analytic mode, the less ‘‘rational’’ mode
is difficult to anticipate and support in any individual.
Unanticipated effects emerge when analytic knowledge is
anticipated as the major underpinning of breast cancer
decision-making.
An interesting artifact of new patterns in breast cancer
decision-making seems to be a decrease in how many
women choose therapies for which random controlled trials
evidence exists: lumpectomy with adjuvant therapy. Study
participants indicated the desire to avoid the subsequent
radiation therapy necessary with BCT, independent of
concerns about body image [63]. Using tools to increase
analytic knowledge, such as in Whelan’s study [77,78], was
perceived as helpful to patients. A large majority (81%)
indicated that the tool helped them make a decision. But a
comparison of surgical choices before and after the
introduction of the decision board noted a decline in the
use of BCT. A subsequent randomized trial by the same
investigators [63] found that patients randomized to the
decision aid stated that they were better informed and more
satisfied with the clinical decision-making, even though they
might not have chosen the alternative associated with clear
scientific evidence.
Redelmeier et al.’s classic article [79] warned that
patients making intuitive decisions were also endangering
their health. These statements lend support to arguments that
providing information will not necessarily lead patients to
the most predictable decisions, particularly in the absence of
a culturally appropriate context. When breast cancer
treatment decision-making is parsed into its components,
it becomes less surprising that ethnic and economically
disadvantaged women not only choose in a manner that
cannot be predicted by physicians, but that outcomes are
relatively poor for these populations.
4. Discussion and conclusion
4.1. Discussion
Emerging patterns of complex interactions between
health status, health care access and delivery, and decision-
making create a maze of possibilities in which women tend
to preserve their own identities and preferences, independent
of the health care authority hierarchy. The health care system
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is not easy to use for anyone, and the fewer resources a
women and her family have, the less manageable the system
will be for extended periods of intervention. One would
wonder if mistrust in the medical care system would almost
preclude identification with the preferred choice of the
physician, especially if the physician does not seem to
empathize with the woman’s life stresses and barriers to
care.
The themes that emerge from the research on decision-
making upon breast cancer diagnosis must be explored in the
context of culture. Those studies already done with women
of ethnically diverse populations deserve clarification and
amplification [6–65,80–83]. To mitigate extant racial,
ethnic, and economic disparities and improve cancer
outcomes for all women, health care providers must
understand what factors can be addressed to decrease
mortality from breast cancer in order to meet goals such as
the Healthy Border 2010 initiative: to decrease breast cancer
mortality by 20% [84].
Treatment decisions are exceptionally complex. The
presentation of factual information, even in well-designed,
comprehensive decision support tools, is perhaps not going
to solve the problem of women choosing breast cancer
treatment options that do not cohere with current research. It
appears that the decision-support tools do provide women
facing breast cancer treatment with information, person-to-
person interaction, and participation in the treatment
process. However, treatment decisions also include cultural
and family considerations that may have nothing to do with
evidence or clinical trials. If disparities in survival are to be
addressed, the entire process and context of breast cancer
treatment decision-making must be understood from the
patient’s perspective.
4.2. Conclusion
As more economically and ethnically diverse groups of
patients are given greater input into their health care
decisions, some choose treatments that may not yield the
greatest health benefit or that may not conform to the
physician’s idea of the ideal treatment for that woman
[45,50]. There is the possibility that a woman’s choice of
mastectomy (despite evidence supporting BCT with
lumpectomy and adjuvant therapy) reflects an inadequate
appreciation for the evidence against that decision. The
decision may also reflect a concomitant avoidance of
inconvenient adjuvant therapies that reflects her taking into
consideration the total impact of her decision on herself and
her family. Health care barriers and the inconvenience of the
health care delivery system for many women, including
those without transportation or childcare, might weigh more
heavily into a woman’s decision than physicians realized. If
those barriers are keeping some women from benefiting
from the treatments that have been shown to improve
survival, health care professionals must mitigate those
barriers to afford all women access to optimal care.
Information cannot convince a woman to choose a
treatment option in isolation from her life’s reality. Thus, in
order to improve the chance of survival from breast cancer in
ethnic women, knowledge and facts must be presented in a
humanistic matrix of emotions, culture, and the reality of
health care delivery for each individual. It may be necessary
to modify the treatment delivery system to support women
of all cultures and economic strata to enable them to tolerate
the treatment regimen.
4.3. Practice implications
The themes that emerge from the research on decision-
making upon breast cancer diagnosis must be explored in the
context of the specific cultures. Those studies already done
with Hispanic women deserve clarification and amplifica-
tion. A large population of women, soon to be the majority
ethnic group in the United States as it is in south Texas,
deserves the best form of support in breast cancer decision-
making. More studies are needed that yield insight into
actual decision-making within the total context of a complex
delivery system and how health care professionals might
encourage and facilitate best practice interventions for those
least likely to choose those interventions. What can be
learned in studying decision-making in breast cancer can
benefit generations of women, no matter their culture,
socioeconomic status, or ethnicity.
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